Welcome to the March edition of INNsight Newsletter, where we share with you the latest news and insights from IQVIA Global Market Insights.
This month's thought leadership includes:
Connect with us
CAR-T Cell Therapy in Cancer Treatment
M&A Activity Rebounds at the End of 2023
Global Trends in R&D 2024: Activity, Productivity, and Enablers
WEBINAR: MIDAS Early Bird – Uncovering the Defining Trends of 2023 and What These Hold for 2024
THOUGHT LEADERSHIP
CAR-T Cell Therapy in Cancer Treatment
Chimeric antigen receptor (CAR)-T cell therapy is a novel form of treatment that is emerging as a transformative approach in cellular immunotherapy. In 2021, the global market for CAR-T cell therapy was estimated to be 1.5 billion USD and it is forecasted to grow to approximately 7.6 billion USD by 2026, demonstrating a compound annual growth rate (CAGR) of 39.1%. Concurrently, the number of CAR-T clinical trials is on the rise, with continual improvements to the CAR-T constructs aimed at boosting their effectiveness and minimizing adverse outcomes. Read more
M&A Activity Rebounds at the End of 2023
Mergers and acquisitions (M&A) in the biopharmaceutical sector experienced a notable resurgence in the fourth quarter of 2023, with an increase in both the overall deal value and volume of these transactions. Despite facing challenges such as macroeconomic factors and regulatory obstacles, biopharmaceutical companies actively pursued substantial M&A endeavors towards the end of 2023 with around 70% of these transactions carried out by big pharma companies and driven by novel, innovative therapies and technologies. Read more
Global Trends in R&D 2024: Activity, Productivity
and Enablers
This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others. Read more
WEBINAR WATCH
WEBINAR: MIDAS Early Bird: Uncovering the defining trends of 2023 and what these hold for 2024
Join us for this special webinar as we uncover the latest pharmaceutical market trends, from post-pandemic recovery to emerging therapy areas, recent launches and transformational developments. From physician engagement to oncology and immunology therapy areas, generics, biosimilars and the developments in diabetes and obesity markets. It takes place on 14 March, 2:30pm CET. Register now and stay ahead of the competition. Register now
Should you have a colleague who is interested in subscribing to this newsletter, please ask them to register here.
Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about IQVIA and our services. Such information also may be transferred to IQVIA companies in other countries.
If you do not wish to receive further information from IQVIA please opt-out. Copyright 2024 IQVIA Holdings Inc. and its affiliates. All rights reserved.
Please note that this message was sent to the following email address: jane.lu3@iqvia.com